文献速递艾滋病与性传播感染

病毒学抑制的泰国HIV感染者转换整合酶链转移抑制剂后的体重变化

Weight change with integrase strand transfer inhibitors among virally suppressed Thai people living with HIV.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

在病毒学抑制的泰国HIV感染者中,比较从非INSTI方案转换为INSTI方案者与继续使用INSTI或非INSTI方案者的体重变化;转换组在病毒学抑制后6、12、18个月体重增加显著大于继续组,至24个月各组体重变化开始趋同;替诺福韦艾拉酚胺使用与体重增加无显著关联。

要点

  • 转换至INSTI方案者在病毒学抑制后6、12、18个月体重增加显著大于继续使用原方案者。
  • 至24个月时,所有方案的体重变化开始趋同。
  • 调整模型中,替诺福韦艾拉酚胺使用与体重增加无显著关联。

核心结论

  • 研究结果提示INSTI相关体重增加的机制超出其控制HIV优于其他抗逆转录病毒药物或「恢复健康」现象所能解释的范围。
  • 需要进一步研究以理解此类体重增加的机制。

研究设计与样本

  • 研究纳入2001年至2020年间有基线体重测量、年龄≥18岁的HIV感染者。
  • 病毒学抑制定义为病毒载量<400拷贝/mL持续6个月。
  • 基线定义为病毒学抑制状态下从非INSTI方案转换为INSTI方案的时间(转换组)或达到病毒学抑制的时间(继续组)。
  • 采用广义估计方程调整年龄、性别和基线体重,对基线后6、12、18和24个月的体重变化建模。

主要发现

  • 共1673例HIV感染者贡献1952次病毒学抑制事件,其中转换组143次(7.3%),继续INSTI组102次(5.2%),继续非INSTI组1707次(87.4%)。
  • 转换组在达到病毒学抑制后6、12和18个月体重增加显著大于继续组。
  • 至24个月时,所有方案的体重变化开始趋同。
  • 调整模型中,替诺福韦艾拉酚胺使用与体重增加无显著关联。

局限性

  • 需要进一步研究以理解此类体重增加的机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We compared weight changes in virally suppressed people living with HIV (PLWH) switching to integrase strand transfer inhibitors (INSTIs) with those remaining on an INSTI or non-INSTI regimen. METHODS: PLWH aged ≥18 years with weight measurements available at baseline between 2001 and 2020 were included. Viral suppression was defined as having had a viral load <400 copies/mL for 6 months. Baseline was defined as the time of switching from a non-INSTI to an INSTI regimen whilst virally suppressed (switch group) or the time that viral suppression was achieved (remain groups). Generalized estimating equations adjusted for age, sex and baseline weight were used to model weight changes 6, 12, 18 and 24 months after baseline. RESULTS: A total of 1673 PLWH contributed 1952 episodes of viral suppression-143 (7.3%) episodes were among PLWH who had switched from a non-INSTI to an INSTI, 102 (5.2%) episodes were among PLWH who remained on an INSTI and 1707 (87.4%) episodes were among PLWH who remained on a non-INSTI. PLWH in the switch group had significantly greater weight gain than those in the remain groups at 6, 12 and 18 months after achieving viral suppression. By 24 months, weight change on all regimens started to converge. Tenofovir alafenamide use was not significantly associated with weight gain in adjusted models. CONCLUSIONS: Our findings suggest that the mechanisms of weight gain due to INSTI use go beyond their superior efficacy over other antiretrovirals in controlling HIV or the effect of the 'return-to-health' phenomenon. Further research is needed to understand the mechanisms of such weight gain.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Han WM, Kerr SJ, Avihingsanon A, et al. Weight change with integrase strand transfer inhibitors among virally suppressed Thai people living with HIV. J Antimicrob Chemother. 2022. PMID: 36101517. doi:10.1093/jac/dkac306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。